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Abstract
Background: Treatment patterns for metastatic castration-resistant prostate cancer
(mCRPC) have changed substantially in the last few years. In trial COU-AA-302
(chemotherapy-naı¨ve men with mCRPC), abiraterone acetate plus prednisone (AA)
significantly improved radiographic progression-free survival and overall survival
(OS) when compared to placebo plus prednisone (P).
Objective: This post hoc analysis investigated clinical responses to docetaxel as ﬁrst
subsequent therapy (FST) among patients who progressed following protocol-speciﬁed
treatment with AA, and characterized subsequent treatment patterns among older
(75 yr) and younger (<75 yr) patient subgroups.
Design, setting, and participants: Data were collected at the ﬁnal OS analysis (96% of
expected death events). Subsequent therapy data were prospectively collected, while
response and discontinuation data were collected retrospectively following discontinu-
ation of the study drug.
Intervention: At the discretion of the investigator, 67% (365/546) of patients from the
AA arm received subsequent treatment with one or more agents approved for mCRPC.
Outcome measurements and statistical analysis: Efﬁcacy analysis was performed for
patients for whom baseline and at least one post-baseline prostate-speciﬁc antigen
(PSA) values were available.
Results and limitations: Baseline and at least one post-baseline PSA values were
available for 100 AA patients who received docetaxel as FST. While acknowledging
the limitations of post hoc analyses, 40% (40/100) of these patients had an unconﬁrmed
50% PSA decline with ﬁrst subsequent docetaxel therapy, and 27% (27/100) had a
conﬁrmed 50% PSA decline. The median docetaxel treatment duration among these
100 patients was 4.2 mo. Docetaxel was the most common FST among older and younger
patients from each treatment arm. However, 43% (79/185) of older patients who
progressed on AA received no subsequent therapy for mCRPC, compared with 17% patients.(60/361) of younger* Corresponding author. Tel. +44-208-7224029; Fax: +44 208 6427979.
E-mail address: johann.de-bono@icr.ac.uk (J.S. de Bono).
Please cite this article in press as: de Bono JS, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate
in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol (2016), http://
dx.doi.org/10.1016/j.eururo.2016.06.033
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0302-2838/# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conclusions: Patients with mCRPC who progress with AA treatment may still derive beneﬁt
from subsequent docetaxel therapy. These data support further assessment of treatment
patterns following AA treatment for mCRPC, particularly among older patients.
Trial registration: ClinicalTrials.gov NCT00887198.
Patient summary: Treatment patterns for advanced prostate cancer have changed sub-
stantially in the last few years. This additional analysis provides evidence of clinical beneﬁt
for subsequent chemotherapy in men with advanced prostate cancer whose disease
progressed after treatment with abiraterone acetate. Older patients were less likely to
be treated with subsequent therapy.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
E U R O P E A N U R O L O G Y X X X ( 2 0 1 6 ) X X X – X X X2
EURURO-6891; No. of Pages 91. Introduction
Prostate cancer is the most common cancer among men
in industrialized countries and represents one of the
leading causes of cancer deaths [1,2]. The mainstay for
treatment of metastatic castration-resistant prostate
cancer (mCRPC) in the past was docetaxel in combination
with androgen deprivation therapy [3–5]. However, treat-
ment patterns for patients with mCRPC have changed
substantially in the last few years following the approval
of five new agents for mCRPC, including androgen
signaling–directed therapy, immunotherapy, and radio-
pharmaceutical products [6–8].
Abiraterone acetate (AA) is a prodrug of abiraterone, a
potent and specific inhibitor of the enzyme 17a-hydroxy-
lase/C17,20-lyase that blocks extragonadal and testicular
androgen biosynthesis [9]. AA (1 g daily) plus prednisone
or prednisolone (5 mg twice daily) is approved for the
treatment of patients with mCRPC on the basis of results
for two pivotal phase 3 trials [10,11]. In patients with
mCRPC who had received prior docetaxel chemotherapy,
treatment with AA improved overall survival (OS) by
4.6 mo (hazard ratio [HR] 0.74, 95% confidence interval
[CI] 0.64–0.86; p < 0.0001) compared to placebo and
prednisone or prednisolone 5 mg twice daily (hereafter
referred to as P) [10,12]. In COU-AA-302, asymptomatic or
mildly symptomatic men with chemotherapy-naı¨ve mCRPC
had significantly better radiographic progression-free
survival (rPFS; HR 0.52; p < 0.0001) and OS (34.7 vs
30.3 mo; HR 0.81, 95% CI 0.70–0.93; p = 0.0033) with AA
compared to P [11,13].
Although the use of sequential therapy is common and
its efficacy is of great interest to clinicians, there is limited
information about subsequent therapy for mCRPC following
treatment with AA. We conducted a post hoc analysis of
COU-AA-302 to evaluate the clinical outcome for docetaxel
as first subsequent therapy (FST) among patients in the AA
treatment arm who experienced disease progression after
protocol-specified treatment with AA and to characterize
subsequent treatment patterns among older (75 yr) and
younger (<75 yr) patient subgroups.
2. Patients and methods
COU-AA-302 (ClinicalTrials.gov NCT00887198) is a phase 3, multina-
tional, randomized, double-blind, placebo-controlled study conducted atPlease cite this article in press as: de Bono JS, et al. Subsequent Ch
in Patients with Metastatic Castration-resistant Prostate Cancer
dx.doi.org/10.1016/j.eururo.2016.06.033151 sites in 12 countries [14]. Patients were enrolled from April 2009 to
June 2010. Patients aged 18 yr with asymptomatic or mildly
symptomatic mCRPC were chemotherapy-naı¨ve and had received
previous anti-androgen therapy. Additional inclusion criteria included
ongoing androgen deprivation with serum testosterone <0.50 ng/ml and
life expectancy of 6 mo. Patients were medically or surgically castrated,
and had tumor progression. Patients with visceral metastases or patients
who had received previous therapy with ketoconazole for >7 d were
excluded.
2.1. Study design
A total of 1088 patients were stratiﬁed by Eastern Cooperative Oncology
Group performance status (0 vs 1) and randomized 1:1 to AA (1000 mg
QD plus P 5 mg BID; n = 546) or placebo plus P (n = 542). All study
personnel were blinded to the patient treatment assignments, and
patient treatment assignments remained blinded at the time of disease
progression. The co-primary end points were rPFS and OS. The primary
and secondary end point results obtained at the time of this analysis
have been described in detail previously [11,13].
As of March 2014, 365 (67%) patients in the AA treatment arm and
435 (80%) in the P arm received subsequent treatment with one or more
agents approved for mCRPC at the discretion of the investigator after
protocol-speciﬁed treatment (Fig. 1) [11]. At the time of data collection,
8% (42/546) of patients continued on AA. The use of a speciﬁc subsequent
therapy for mCRPC was not proscribed in the study, but these data were
collected prospectively, while response and discontinuation data on
subsequent therapy were collected retrospectively after patients
discontinued the study drug. Data that could be accessed for these
patients were included in the current analysis. Efﬁcacy analysis was
performed among patients from the AA treatment arm with available
baseline prostate-speciﬁc antigen (PSA) within 30 d before the ﬁrst dose
of docetaxel and at least one post-baseline PSA value. As recommended
by the Prostate Cancer Clinical Trials Working Group (PCWG2) [15], PSA
response was deﬁned as a 50% PSA decline from baseline with at least
two available PSA values measured 3–4 wk apart. Unconﬁrmed 50%
PSA declines were deﬁned as a 50% PSA decline from baseline with at
least one available PSA value. Reasons for discontinuation were
investigator reported without speciﬁc criteria. Efﬁcacy data for
subsequent therapy were not collected for patients from the P arm.
2.2. Statistical analyses
All data for the current analyses were collected at the ﬁnal OS analysis
(96% of expected death events). On the basis of the aggregate efﬁcacy and
safety data at the second interim analysis (clinical cutoff December
2011), the independent data-monitoring committee unanimously
recommended unblinding in February 2012, 20 mo after the last patient
was enrolled. To characterize subsequent therapy and treatment
patterns by age subgroup, patients were dichotomized by age at 75 yr.emotherapy and Treatment Patterns After Abiraterone Acetate
: Post Hoc Analysis of COU-AA-302. Eur Urol (2016), http://
Fig. 1 – CONSORT diagram. a Abiraterone acetate, cabazitaxel, enzalutamide, ketoconazole, or sipuleucel-T.
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[16] and COU-AA-301 [17] and is consistent with US regulatory guidance
to deﬁne a geriatric population in clinical trials [18]. Clinical progression
data were obtained from investigator reports, and data on responses and
subsequent therapy for mCRPC were collected by trial monitors during
site visits. The data were then source-veriﬁed and entered into the
database. PSA response rates and post-treatment PSA declines were
summarized using frequency and percentages. The time to PSA
progression (TTPP) was estimated using PCWG2 criteria and included
censored patients. Median TTPP with 95% CI was estimated using the
Kaplan-Meier method.Table 1 – Baseline characteristics of the ITT population and patients w
D
Patients (N) 26
Median age, yr (range) [n] 69
Median time from ID to FD, yr (range) [n] 4.
Median PSA at ID, ng/ml (range) [n] 23
Gleason score 8 at ID, n/N (%) 12
Extent of disease, n/N (%)
Bone only 13
Soft tissue a or node 12
Other 1/
ECOG PS, n/N (%)
0 20
1 55
Prior prostate cancer therapy, n/N (%)
Surgery 12
Radiotherapy 13
Hormonal 26
Other 39
Median baseline PSA, ng/ml (range) [n] 48
Median baseline LDH, IU/l (range) [n] 18
Median baseline ALP, IU/l (range) [n] 10
ITT = intention to treat; FST = ﬁrst subsequent therapy; AA = abiraterone acetat
Cooperative Oncology Group performance status; PSA = prostate-speciﬁc antigen
a Excludes visceral metastases.
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Baseline characteristics for patients who progressed on
AA and received docetaxel as FST were similar to the full
COU-AA-302 intention-to-treat (ITT) population (Table 1).
Among patients in the AA arm, 36% (194/546) and 15% (83/
546) had two or more and three or more subsequent
therapies, respectively (Table 2). Among those in the P arm,
45% (243/542) and 22% (121/542) had two or more and
three or more subsequent therapies, respectively.ho received docetaxel as FST
COU-AA-302 AA treatment arm
ocetaxel as FST ITT population
1 546
 (44–93) [261] 71 (44–95)
4 (<1–28) [261] 5.5 (<1–28) [542]
 (2–5036) [236] 22 (0.4–5036) [470]
9/244 (53) 263/488 (54)
2/261 (51) 274/542 (51)
8/261 (49) 267/542 (49)
261 (<1) 4/542 (<1)
6/261 (79) 423/546 (76)
/261 (21) 133/546 (24)
5/261 (48) 256/544 (47)
8/261 (53) 283/544 (52)
1/261 (100) 544/544 (100)
/261 (15) 82/544 (15)
 (1–3266) [261] 42 (0–3927) [546]
9 (60–871) [261] 187 (60–871) [543]
3 (32–1927) [261] 93 (32–1927) [546]
e plus prednisone; ID = initial diagnosis; FD = ﬁrst dose; ECOG PS = Eastern
; LDH = lactate dehydrogenase; ALP = alkaline phosphatase.
motherapy and Treatment Patterns After Abiraterone Acetate
: Post Hoc Analysis of COU-AA-302. Eur Urol (2016), http://
Table 2 – Subsequent therapy for metastatic castration-resistant
prostate cancer following discontinuation of protocol-specified
study drug
AA P
Patients 546 542
Any subsequent therapy 365 (67.0) 435 (80.3)
Two or more subsequent therapies 194 (36.0) 243 (45.0)
Three or more subsequent therapies 83 (15.2) 121 (22.3)
No subsequent therapy 139 (25.4) 107 (19.7)
Protocol-speciﬁed treatment ongoing 42 (7.7) 0
AA = abiraterone acetate plus prednisone; P = placebo plus prednisone.
Data are presented as n (%).
Table 4 – Treatment duration and discontinuation reasons for
261 patients who received FST with docetaxel
Median duration of docetaxel as FST, mo (IQR) a 3.02 (0.95–5.72)
Reason for discontinuation per investigator, n (%) b
Clinical progression 38 (15)
Radiographic progression 36 (14)
Prostate-speciﬁc antigen progression 75 (29)
Adverse event 41 (16)
Therapy ongoing 11 (4)
Other 73 (28)
FST = ﬁrst subsequent therapy; IQR = interquartile range.
a Start and end dates for docetaxel therapy were known for 235 patients.
Among 100 patients for whom baseline and at least one post-baseline
prostate-speciﬁc antigen values were available, the median duration was
4.17 mo (IQR 2.79–6.37).
b During ﬁrst subsequent therapy with docetaxel. Reasons were based on
investigator judgment without speciﬁc criteria; more than one reason was
selected for 39 patients.
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FST included taxane chemotherapy, androgen signaling–
directed therapy, and immunotherapy (Table 3). Overall,
there was low prevalence of cabazitaxel and enzalutamide
as FST. Docetaxel was by far the most common FST in the AA
arm (48%, 261/546) and in the P arm (50%, 272/542). The
median duration of docetaxel therapy following AA was
3.0 mo (interquartile range [IQR] 0.95–5.7; Table 4). The
reason most commonly reported for discontinuation of
docetaxel as FST was PSA progression, although more than
one reason was reported for 39 patients. Toxicity appeared
to be a fairly infrequent reason for docetaxel discontinua-
tion, even though these patients had advanced disease and
previous medical therapy for mCRPC.
A total of 100 AA patients who received docetaxel as FST
had post-trial baseline and post-baseline PSA values
available. Among these 100 patients the median duration
of docetaxel therapy was 4.2 mo (IQR: 2.8–6.4). However,
data on the median number of docetaxel courses adminis-
tered were not available. The rate of post-treatment PSA
decline 50% was 40% (40/100), including the 27 patients
with a confirmed response (PSA response rate 27%; Fig. 2).
TTPP was estimated based on 29 events and 71 censored
patients. The median TTPP for these 100 patients was
7.6 mo (95% CI 5.0 to not estimable; Supplementary Fig. 1).
The major reasons for censoring were the proportion of
patients who did not have PSA progression and those who
had PSA progression but did not have complete PSA data
available because of retrospective data collection.Table 3 – First subsequent therapy for metastatic castration-
resistant prostate cancer
AA P
Patients 546 542
Taxane chemotherapy
Docetaxel 261 (48.0) 272 (50.2)
Cabazitaxel 4 (<1) 3 (<1)
Androgen synthesis inhibitor
Abiraterone acetate 13 (2.4) 80 (14.8)
Ketoconazole 36 (6.6) 56 (10.3)
Androgen receptor antagonist (enzalutamide) 20 (3.7) 4 (<1)
Immunotherapy (sipuleucel-T) 31 (5.7) 20 (3.7)
AA = abiraterone acetate plus prednisone; P = placebo plus prednisone.
Data are presented as n (%).
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The treatment patterns by age subgroup are shown in
Fig. 3and Supplementary Tables 1 and 2. In the overall ITT
population, 15% (114/738) of younger patients received no
subsequent therapy, compared with 38% (132/350) of older
patients (Supplementary Table 1). The proportion of
patients who died without receiving subsequent therapy
followed the same pattern (Supplementary Table 1).
Moreover, 43% (79/185) of older patients with progression
on AA did not receive subsequent therapy for mCRPC
following discontinuation of the protocol-specified study
drug. Docetaxel was the most common FST among older and
younger patients in each treatment arm. More than half of
younger patients from both treatment arms received
docetaxel as FST: 55% (197/361) in the AA arm and 56%
(210/377) in the P arm. By contrast, 35% (64/185) and 38%
(62/165) of older patients from the AA and P arms,
respectively, received docetaxel as FST. Similar trends were
observed when treatment patterns were assessed according
to the mCRPC drugs used in any sequence (Supplementary
Table 2). For both younger and older patients in the P arm,
the subsequent therapy most commonly used was doc-
etaxel and AA. Cabazitaxel was more commonly used as
subsequent therapy among younger compared to older
patients.
4. Discussion
This post hoc analysis characterized subsequent therapy
and treatment patterns among patients with mCRPC who
progressed on AA. Patients were commonly treated with
subsequent therapy, although older patients were almost
three times more likely not to receive any subsequent
therapy in comparison younger patients. Docetaxel was the
FST for a large majority of patients, irrespective of age
group.
The observed post-treatment PSA declines 50%support
an antitumor effect of docetaxel as FST in some patients
who progressed with AA. Although 27% of patients had a
confirmed PSA response, the data overall on PSA declineemotherapy and Treatment Patterns After Abiraterone Acetate
: Post Hoc Analysis of COU-AA-302. Eur Urol (2016), http://
AB
Fig. 2 – Unconfirmed PSA declines among patients treated with abiraterone acetate who received docetaxel as first subsequent therapy. (A) Maximum
PSA decline from baseline. (B) Total and confirmed post-treatment PSA decline. Waterfall plot with maximum PSA change and PSA response rate for
patients with available baseline PSA within 30 d of subsequent docetaxel therapy and at least one post-baseline PSA value. PSA = prostate-specific
antigen; AA = abiraterone acetate plus prednisone.
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the post-AA setting. The median TTPP was 7.6 months
which would be, similar to that from contemporaneous
reports of AA-naı¨ve patients treated with docetaxel in large
phase 3 trials [19–21]. However, this observation needs to
be interpreted with caution owing to the high censoring
rate (71%), which is likely to have led to overestimation of
this value. Moreover, the median duration of docetaxel
therapy was based on patients with known docetaxel start
and end dates, whereas the median number of docetaxel
courses administered may not have been captured. With
this consideration, the median treatment duration in the
100-patient cohort described here was 4.2 mo, compared to
7.7 mo in the TAX-327 trial. The confirmed PSA response
rate among patients from the AA arm who received
docetaxel as FST was 27%, which is lower than the 45%
rate reported for docetaxel therapy for mCRPC in the phase
3 TAX-327 study [4]. However, the rate of confirmed and
unconfirmed post-treatment PSA decline 50% was 40%,
which is closer to the TAX-327 findings. In addition, patientsPlease cite this article in press as: de Bono JS, et al. Subsequent Che
in Patients with Metastatic Castration-resistant Prostate Cancer
dx.doi.org/10.1016/j.eururo.2016.06.033in TAX-327 may have been vigorously selected and
prescreened in terms of performance status and prognosis
as part of the eligibility criteria for the trial, which
specifically investigated docetaxel use.
There is conflicting evidence that mCRPC patients who
experience disease progression after androgen signaling–
directed therapy may be less responsive to taxane-based
chemotherapy. Such cross-resistance could possibly be
mediated in part by taxane-induced disruption of androgen
receptor (AR) trafficking along microtubules [22]. Results
from two retrospective studies suggest partial cross-
resistance between AA and docetaxel. In a study by
Mezynski et al. [23], subsequent therapy with docetaxel
resulted in PSA declines 50% in 26% of cases and a median
TTPP of 4.6 mo (95% CI, 4.2–5.9) among mCRPC patients
previously treated with AA (n = 35). In a second study [24],
mCRPC patients who received AA before docetaxel (n = 24)
had median PFS of 4.1 mo compared to 6.7 mo in the
docetaxel-only group (p = 0.002). In the same study, PSA
declines 50% were less frequent among patients whomotherapy and Treatment Patterns After Abiraterone Acetate
: Post Hoc Analysis of COU-AA-302. Eur Urol (2016), http://
<75 yr ≥75 yr
<75 yr ≥75 yr <75 yr ≥75 yr
Docetaxel as first subsequent therapy No subsequent therapy
A
B
Fig. 3 – First subsequent therapy by age subgroup. (A) Docetaxel as first subsequent therapy and no subsequent therapy. (B) All first subsequent
therapy. AA = abiraterone acetate plus prednisone; P = placebo plus prednisone.
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however, PSA responses to docetaxel were observed in
30% (7/23) of men previously treated with AA [24]. In
addition, other reports have suggested no or minimal cross-
resistance between AA and docetaxel [25] and between
ketoconazole and docetaxel [26]. Additional results sup-
porting a clinical benefit for taxane-based chemotherapy
following AA were reported by Al Nakouzi et al. [27]. In this
retrospective study of 79 patients with progressive mCRPC
after docetaxel and AA, PSA declines 50% were achieved in
35% (28/79) of patients who received subsequent therapy
with cabazitaxel [27].
The potential role of AR splice variants as a resistance
mechanism is further evidence that all subsequent therapy
for mCRPC may not be effective [28]. In a prospective study
of 62 men with mCRPC, detection of AR-V7 mRNA in
circulating tumor cells was associated with resistance to AA
and enzalutamide [29]. Results from two retrospective
studies suggest that the effects of AA following enzaluta-
mide treatment for mCRPC are associated with limited
response rates for chemotherapy-pretreated and chemo-
therapy-naı¨ve men [30,31]. Similar observations were
reported for enzalutamide following AA treatment
[32]. However, a recent report suggests that AR-V7 is not
associated with primary resistance to taxane chemotherapy
[33]. Thus, it is plausible that some patients in the current
analysis progressed on AA treatment because of AR-V7, but
retained sensitivity to docetaxel. Overall, our results
suggest that a proportion of AA-unresponsive patientsPlease cite this article in press as: de Bono JS, et al. Subsequent Ch
in Patients with Metastatic Castration-resistant Prostate Cancer
dx.doi.org/10.1016/j.eururo.2016.06.033may still derive a benefit from subsequent therapy with
docetaxel.
The treatment of mCRPC is evolving rapidly and there
may be geographic differences in terms of regional practice
patterns and available agents. While COU-AA-302 was an
international study, the availability of other drugs approved
for mCRPC (including enzalutamide, radium-223, and
cabazitaxel) varied by country, and this may have
influenced post-AA treatment patterns. In addition, subse-
quent to the conclusion of COU-AA-302, information from
two data sets emerged to support the use of upfront
docetaxel in the metastatic hormone-sensitive setting. The
impact of docetaxel in this earlier application on post-AA
treatment patterns and treatment efficacy will need to be
evaluated in future studies.
A substantial proportion (43%) of patients aged 75 yr
who progressed with AA received no subsequent therapy
with mCRPC drugs, suggesting that treatment nihilism may
exist, in part potentially because of the toxicity profile of
docetaxel in this population, although patient acceptance
and other disease characteristics may also be factors
[34,35]. Although the proportion of older patients receiving
no subsequent therapy is high, this finding is consistent
with other observations of treatment patterns among
elderly men with mCRPC [36,37]. Interestingly, a high
proportion of patients in the AA treatment arm received
subsequent therapy, suggesting that patients remained fit
enough for subsequent therapy after progression on AA.
Overall, these observations suggest that the favorableemotherapy and Treatment Patterns After Abiraterone Acetate
: Post Hoc Analysis of COU-AA-302. Eur Urol (2016), http://
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mCRPC patients, especially older men, to receive effective
mCRPC medical therapy. Treatment patterns are important
for older patients with mCRPC for several reasons. In
comparison to younger patients, elderly men are more
likely to present with advanced disease [38]. Although age-
related changes may affect the risk of toxicities, age alone
should not prevent patients from deriving benefit from
cancer treatment [38,39]. Indeed, the clinical benefit of AA
and enzalutamide among elderly patients with mCRPC has
been demonstrated in post hoc analyses for randomized,
double-blind phase 3 trials [16,17,40].
There are several important limitations to the analysis.
Subsequent therapy and treatment patterns were evaluated
retrospectively, and no specific end points were defined;
investigators were instructed to follow PCWG2 criteria.
Since patients were under routine clinical care and no
longer on trial, PSA data were not available for most patients
to confirm PSA response or progression data, and thus there
was a high censoring rate. Among the 261 AA patients who
received docetaxel as FST, post-trial baseline and post-
baseline PSA values were not available for 161 men. Thus,
the confirmed PSA response was limited to the 100 patients
with baseline and post-baseline PSA values available, which
may have introduced selection bias. For example, patients
who progressed rapidly on docetaxel may be under-
represented in the analysis compared to patients who
had a more favorable clinical course and possibly more
folllow-up PSA data available.
5. Conclusions
This post hoc analysis for chemotherapy-naı¨ve patients
with mCRPC who experienced disease progression on AA
suggests that docetaxel has meaningful antitumor activity
as FST. While acknowledging the limitations of a retrospec-
tive analysis, our observations suggest that docetaxel may
be considered for patients with mCRPC who progress on AA
treatment. A substantial proportion of older patients with
mCRPC who progressed on AA received no subsequent
therapy with drugs approved for mCRPC. This may be
explained by a broader group of mCRPC patients considered
eligible for first-line AA therapy but not considered
candidates for other subsequent mCRPC treatments such
as docetaxel after progression on AA. Taken together, these
data indicate that further assessment of subsequent therapy
and treatment patterns following AA treatment for mCRPC
is warranted, particularly among older patients.
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